Nasdaq

FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any ...

SAN FRANCISCO and DUBLIN, Oct. 28, 2019 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, and Allergan plc (NYSE: AGN), a ...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety ...
Medscape

Levonorgestrel-Releasing Intrauterine System May Reduce Menstrual Blood Loss

August 26, 2010 — For women with documented idiopathic heavy menstrual bleeding, the levonorgestrel-releasing intrauterine system is associated with a greater reduction in menstrual blood loss and a ...
Insurancenewsnet.com

Estimated Economic Impact of the Levonorgestrel Intrauterine System on Unintended Pregnancy in Active Duty Women

Nearly half of all pregnancies in the United States are unin- tended,1 which is defined as any pregnancy either mistimed, unplanned, or unwanted.2,3 Prior studies on unintended preg- nancy in the ...
News Medical

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA™ ...
Medscape

Levonorgestrel System Eases Effects of Menorrhagia

A levonorgestrel-releasing intrauterine system was more effective than usual medical treatments in alleviating the adverse effects of menorrhagia on women's lives, a 2-year primary care–based study ...
PharmiWeb

Levosert® (52mg levonorgestrel intrauterine system [IUS]) receives an 8-year licence extension in the UK for contraception

· Levosert is effective for 8 years in the contraception indication and has demonstrated efficacy for 3 years in the indication of heavy menstrual bleeding. 1 Therefore, Levosert should be removed or ...
MedPage Today

Levonorgestrel IUD Safe, Effective for 5 Years of Contraceptive Use

Levonorgestrel intrauterine system is safe and efficacious for contraception over a 5-year period, data from a phase III trial found. Pearl Indices, or the number of unintentional pregnancies, for ...
Healio

Levonorgestrel IUD reduces blood loss by more than 90% in those with heavy menstrual bleeding

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The Liletta levonorgestrel-releasing intrauterine device ...
Healio

Long-acting intrauterine contraceptive device may raise breast cancer risk

Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...
Pharmabiz

Bayer initiates phase III study SUNFLOWER with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia

Bayer initiates phase III study SUNFLOWER with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia: Berlin Wednesday, December 3, 2025, ...
EurekAlert!

Breast cancer in users of levonorgestrel-releasing intrauterine systems

About The Study: This Danish nationwide study found an association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and increased breast cancer risk in females ages 15 to 49, ...